feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

FDA approves Wegovy pill

trending

Chris Rea dead at 74

trending

Belichick hires Bobby Petrino

trending

S&P 500 index rises

trending

South Africa vs Angola AFCON

trending

Napoli vs Bologna Supercoppa

trending

Helen Siff dead at 88

trending

Arizona tops AP poll

trending

Porto eyes Primeira Liga lead

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / FDA Approves Oral Wegovy: Game Changer for Dieters?

FDA Approves Oral Wegovy: Game Changer for Dieters?

23 Dec

•

Summary

  • FDA approved the first oral version of the popular Wegovy weight loss drug.
  • The pill requires strict adherence for maximum weight loss results.
  • Oral GLP-1 drugs may offer less weight loss than injections.
FDA Approves Oral Wegovy: Game Changer for Dieters?

The Food and Drug Administration has granted approval for an oral version of Wegovy, Novo Nordisk's widely recognized weight loss medication. This marks the introduction of the first pill form for a GLP-1 drug specifically for weight management, with a similar option from Eli Lilly anticipated soon. These GLP-1 compounds, initially for diabetes, have surged in popularity due to their effectiveness in facilitating significant weight loss.

Dr. Christopher McGowan highlighted the pill's potential to broaden treatment options, noting that pills are often more psychologically acceptable and easier to integrate into daily routines than injections. While the exact list price is unreleased, it's expected to be lower than injectable versions. Clinical trials indicate that the highest dose of the Wegovy pill led to an average weight loss of 16.6% over 64 weeks, comparable to its injectable form.

However, maintaining strict adherence to the daily regimen—taking the pill first thing in the morning on an empty stomach with water—is critical, as deviations resulted in less weight loss in trials. Gastrointestinal side effects, such as nausea and vomiting, are common, potentially intensified by the pill's immediate release. Experts are still evaluating its 'real-world performance' regarding patient compliance and long-term efficacy.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The FDA approved the first oral version of Wegovy, a GLP-1 drug for weight loss, to be taken daily.
Clinical trials showed the highest dose of the Wegovy pill led to an average 16.6% body weight loss over 64 weeks.
Common side effects include nausea and vomiting, which may feel more intense due to the pill's immediate release.

Read more news on

Healthside-arrow

You may also like

FDA Eyes Fast-Track for Merck's Blockbuster Drugs

18 Dec • 47 reads

article image

FDA Probes COVID Vaccine Deaths in Adults & Kids

11 Dec • 71 reads

FDA Proposes Catch-Up for US Sunscreen Standards

12 Dec • 72 reads

article image

Indian Pharma Shifts Gears: Beyond US Generics

7 Dec • 103 reads

article image

New Glasses Slow Kids' Nearsightedness

1 Dec • 140 reads